ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0211 • ACR Convergence 2020

    Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs

    Xiaofeng Zeng1, Dongbao Zhao2, Sebastiao Radominski3, Mauro Keiserman4, Chang Keun Lee5, Sebastian Meerwein6, Jeffrey Enejosa7, Yunxia Sui7, Mohamed-Eslam Mohamed7 and Won Park8, 1Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), 2Shanghai Changhai Hospital, Shanghai, China (People's Republic), 3Universidade Federal do Paraná, Curitiba, Brazil, 4Pontificial Catholic University, Porto Alegre, Brazil, 5Asan Medical Center, Seoul, Republic of Korea, 6Pharmaceutical Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, 7AbbVie Inc., North Chicago, IL, 8Inha University, Incheon, Republic of Korea

    Background/Purpose: This Phase 3, randomized, double-blind, placebo (PBO)-controlled study assessed the efficacy and safety of upadacitinib (UPA) in combination with csDMARDs in patients with rheumatoid…
  • Abstract Number: 0228 • ACR Convergence 2020

    Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study

    Eduardo Mysler1, Yoshiya Tanaka2, Arthur Kavanaugh3, Daniel Aletaha4, Peter Taylor5, In-Ho Song6, Tim Shaw6, Yanna Song7, Ryan DeMasi6, Mira Ali6 and Roy Fleischmann8, 1Organización Medica de Investigación, Buenos Aires, Argentina, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 3Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 4Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, 5Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., North Chicago,, IL, 8Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: In the randomized, double-blinded, Phase 3 SELECT-COMPARE study, upadacitinib (UPA) + MTX demonstrated greater clinical and functional responses vs adalimumab (ADA) + MTX in…
  • Abstract Number: 0431 • ACR Convergence 2020

    Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients

    Elizabeth Park1, Jon Giles2, Thania Perez-Recio1, Paloma Pina3, Christopher Depender1, Joan Bathon1 and Laura Geraldino-Pardilla4, 1Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 2Columbia University, New York, NY, 3Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, 4Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York

    Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
  • Abstract Number: 0488 • ACR Convergence 2020

    Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database

    Sebastian Sattui1, Iris Navarro-Millan2, Fenglong Xie3, Mangala Rajan2, Huifeng Yun4 and Jeffrey R Curtis4, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, 3University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: There is growing interest regarding the role of neuroinflammation in the development of dementia and the potential role for anti-inflammatory therapy, including TNF-inhibitors (TNFi),…
  • Abstract Number: 0635 • ACR Convergence 2020

    Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients

    Bonnia Liu1, Victor Yang2, Christopher McMaster3, Russell Buchanan4, Albert Frauman5 and David Liew6, 1Austin Health, Heidelberg, Victoria, Australia, Macleod, Victoria, Australia, 2Austin Health, Heidelberg, Victoria, Australia, Glen Waverley, Victoria, Australia, 3Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, 4Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia, 5Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, 6Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia

    Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…
  • Abstract Number: 0753 • ACR Convergence 2020

    Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort

    Stéphanie de Montjoye1, Tatiana Sokolova1, Emilie Sapart1, Bernard Lauwerys2, Stéphanie Dierckx3, Christine Galant4, Laurent Meric de Bellefon1, Adrien Nzeusseu Toukap5, Clément Triaille6 and Patrick Durez7, 1Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 2Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 3Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, 43Pathology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, 51Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, 6Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, 7Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

    Background/Purpose: Rheumatoid arthritis is a heterogeneous disease with different clinical presentation and prognostic factors including the immune process in the synovium. The development of ultrasound-guided…
  • Abstract Number: 0770 • ACR Convergence 2020

    Effect of Citrullination on the Processing and Presentation of Rheumatoid Arthritis Autoantigens

    Ashley Curran1, Jonathan Crawford1 and Erika Darrah1, 1Division of Rheumatology, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Citrullinated proteins are hallmark targets of the autoimmune response in rheumatoid arthritis (RA), but the mechanism by which immune tolerance is broken to these self-proteins…
  • Abstract Number: 0787 • ACR Convergence 2020

    MerTK Synovial Expression Correlates with Disease Activity and Treatment Response in Rheumatoid Arthritis Patients

    Alessandra Nerviani1, Marie-Astrid Boutet1, Giulia Maria Ghirardi2, Gloria Lliso-Ribera2, Felice Rivellese1, Myles Lewis1, Michele Bombardieri2, Frances Humby2 and Costantino Pitzalis2, 1Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, 2Queen Mary University of London, London, United Kingdom

    Background/Purpose: Despite valuable improvements in long-term clinical outcomes, a significant portion of rheumatoid arthritis (RA) patients still do not adequately respond to available treatments, and…
  • Abstract Number: 0804 • ACR Convergence 2020

    Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands

    Elise van Mulligen1, Saad Ahmed1, Angelique Weel2, Mieke Hazes3, Annette van der Helm - van Mil4 and Pascal de Jong1, 1Erasmus MC, Rotterdam, Netherlands, 2Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, 3Erasmus Medical Center, Rotterdam, Netherlands, 4Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…
  • Abstract Number: 0821 • ACR Convergence 2020

    Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry

    Vijaya Rivera1, Sandra Sicsik Ayala1, David Vega Morales2, Fedra Irazoque-Palazuelos3, Dafhne Miranda Hernández1, Julio Casasola Vargas1, Sandra Carrillo Vázquez1, Angélica Peña Ayala1, Angel Castillo Ortiz1, Omar Muñoz Monroy1, Sergio Durán Barragán1, Aleni Paz Viscarra1, Estefanía Torres Valdez1, Daniel Xibille Friedmann1, Erick A Zamora Tehozol4, Luis Valdés Corona1, Azucena Ramos Sánchez1, Natalia Santana Portillo1, Francisco Guerrero Díaz1, Miguel Vazquez Zaragoza1, Claudia Zepeda Moreno1, Kitzia Alvarado Sánchez1, Melanea Rivera Valencia1, Cesar Pacheco Tena5 and Deshire Alpizar-Rodriguez6, 1Colegio Mexicano de Reumatología, Mexico City, Mexico, 2Universidad Autónoma de Nuevo León, Garcia, Mexico, 3Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, 4Centro Médico Pensiones, Merida, Yucatan, Mexico, 5Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, 6Colegio Mexicano de Reumatología, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and is more frequent and severe in women than in men. Symptom severity, disease progression,…
  • Abstract Number: 0949 • ACR Convergence 2020

    SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation

    Daimon Simmons1, Hung Nguyen2, Emma Gomez-Rivas3, YunJu Jeong4, William Apruzzese5, Edy Kim6 and Michael Brenner7, 1Department of Pathology, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Brigham and Women's Hospital,, Boston, MA, 3Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 4Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boston, MA, 5., Boston, 6Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Monocytes orchestrate immune responses that protect against microbes but can also drive pathological inflammation and autoimmune disease. Monocytes are thought to be activated primarily…
  • Abstract Number: 1002 • ACR Convergence 2020

    Prostate Cancer Risk Is Not Increased in Rheumatoid Arthritis After Accounting for Retention in a Health Care System

    Kaitlyn Brittan1, Punyasha Roul1, Joshua Baker2, Yangyuna Yang1, Brian Sauer3, Namrata Singh4, Harlan Sayles1, Grant Cannon5, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Utah, Omaha, NE, 4University of Washington, Bellevue, WA, 5Salt Lake City VA Medical Center and University of Utah, Salt Lake City

    Background/Purpose: Patients with rheumatoid arthritis (RA) may have up to a 15% increased risk of prostate cancer per a recent meta-analysis (Simon et al. Arthritis…
  • Abstract Number: 1018 • ACR Convergence 2020

    Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)

    Lijun Wu1, Zhanyun Da2, Hongzhi Wang3, Jianlin Huang4, Bin Wu5, Henglian Wu6, Fang He7, Fen Wang8, Rong Du9, Linchong Su10, Qiaoqiao Yao11, Rui Wu12, Zhenbin Li13, Xiaohan Wang14, Yuhong Liu9, Chuanjing Li15, Xiaomei Lei16, Minjun Wang17, Hui Xiao17, Yuhua Jia18, Yihong Liu17, Xin Chen17, Shengsong Jia17, Bing Wu18, Yuan Liu17, Fei Xiao18 and Lingli Dong19, 1People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), 2The affiliated Hospital of Nantong University, Nantong, Jiangsu, China (People's Republic), 3The First Hospital of Jiaxing, Jiaxing, China (People's Republic), 4The sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), 5Chongqing Hospital of Traditional Chinese Medicine, chongqing, Chongqing, China (People's Republic), 6Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), 7Suining Central Hospital, Suining, Sichuan, China (People's Republic), 8The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), 9Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), 10Minda Hospital of Hubei Minzu University, Enshi, Hubei, China (People's Republic), 11China Resources Wuhan Iron and Steel General Hospital, Wuhan, Hubei, China (People's Republic), 12The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), 13Chinese people ’s liberation army joint service support force 980 hospital, shijiazhuang, Jiangxi, China (People's Republic), 14Anyang district hospital, Anyang, Henan, China (People's Republic), 15Xiaogan Central Hospital of Hubei Province, Xiaogan, Hubei, China (People's Republic), 16Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), 17Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), 18Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), 19Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic)

    Background/Purpose: Treat-to-Target(T2T) is the main therapeutic strategy for patients with RA and SLE. There has been no report on comparation of seasonal variations on T2T…
  • Abstract Number: 1189 • ACR Convergence 2020

    Serum High-sensitive Cardiac Troponin at Baseline Predict Cardiovascular Events in Rheumatoid Arthritis and Osteoarthritis

    M. Elaine Husni1, Daniel H Solomon2, Mingyuan Shao3, Katherine Wolski3, Steven Nissen3, Stanley Hazen4 and WH Wilson Tang4, 1Cleveland Clinic, Cleveland, OH, 2Brigham and Women's Hospital, Boston, MA, 3Cleveland Clinic Foundation, Cleveland, OH, 4Cleveland Clinic Foundation, Cleveland

    Background/Purpose: In rheumatoid arthritis (RA), excess mortality and inflammation has been attributed to cardiovascular (CV) diseases. High-sensitivity cardiac troponins (hscTnT) allow measurement of cardiac troponin…
  • Abstract Number: 1205 • ACR Convergence 2020

    Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of One-year Anti-TNF-α Therapy

    Anita Pusztai1, Attila Hamar2, Ágnes Horváth2, Katalin Gulyás2, Edit Végh2, Nóra Bodnár2, György Kerekes2, Monika Czókolyová2, Szilvia Szamosi2, Levente Bodoki2, Katalin Hodosi2, Andrea Domján2, Gábor Nagy2, Luis Lopez3, Ejii Matsuura4, Zoltán Prohászka5, Sándor Szántó2, Zoltán Nagy2, Yehuda Shoenfeld6, Zoltán Szekanecz2 and Gabriella Szűcs2, 1University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, 2University of Debrecen, Debrecen, Hungary, 3Corgenix Inc., Broomfield, CO, 4Okayama University, Okayama, Japan, 5Semmelweis University, Budapest, Hungary, 6Zabludowicz Center, Tel-Hashomer, Israel

    Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with cardiovascular (CV) disease. The treatment of arthritis by tumour necrosis factor α (TNF-α)…
  • « Previous Page
  • 1
  • …
  • 148
  • 149
  • 150
  • 151
  • 152
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology